ICSTI Statement on Nanotechnology - Forfás

More documents

Recommendations

Info

3.1 Application Areas Nanotechnology is about making existing materials/devices better (called passive applications) and making materials/devices never before possible (called active applications). The distinction between these applications also indicates the likely rate of adoption of the technology by industry and also the industry segments that are likely to adopt them. Passive applications are already in the market (GM, Toyota, tennis balls) and offer the potential for established companies to develop or maintain their competitive advantage by applying the technology to their products or processes. Active applications have a longer time horizon and will be the source of new start-up companies and will form the basis for radical technological change in multinational corporations. It is difficult to forecast the market value for nanotechnology applications. In the case of many active applications the market does not yet exist (e.g. non-CMOS electronics). In the case of passive applications it depends on the extent to which the technology will penetrate specific markets and/or which of the competing technologies will dominate. For example both nanoparticles and carbon nanotubes are both excellent drug delivery systems, but it as yet unclear, which will dominate the market. To simplify the identification of the end markets and potential market size the following top-level application areas are discussed. Electronics Pharmaceuticals Medical devices and biotechnology products Chemicals & Materials Energy 91
92 3.1.1 Electronics The electronics semiconductor market is currently dominated by silicon-based technologies. The market is demanding device miniaturisation with increased performance (i.e. increased processing speed, greater data storage capacity, reduced energy consumption). Nanotechnology is identified as a route to increased performance and significant size reduction. The European Commission estimates that the value for non-CMOS semiconductors will be between 5% and 7% of the total electronics chip market by 2004. This equates to a market valuation of €15 billion to €30 billion for electronics applications of nanotechnology by 2004. One of the goals in electronics is to use individual atoms or molecules as electronic components, which will enable significant size reductions with increased performance. Moore’s Law predicts the size reduction of integrated circuits with time. To continue its recent trend the industry must move rapidly into the nanosized domain using methods other than the current top-down approach. 3.1.2. Pharmaceuticals. The pharmaceutical industry is driven by regulation and market demand for more effective, lower dose drugs with fewer side effects. Nanomaterials have the potential as drug delivery vehicles to both target specific organs and only dose the drug in response to specific triggers from the body. The UK Department of Trade and Industry (UK-DTI) estimates that by 2015 50% of all pharmaceutical production will depend on nanotechnology. This equates to a market value of c €3.5 billion. For example, many drug systems have been developed but never marketed due to their poor solubility in water. Elan has developed a proprietary milling system (NanoCrystal‚) that reduces the size of the drug particles to the nano size domain. This allows the particles to be suspended in a liquid and the drug delivered orally.
Page 1 and 2:
I C STI I R E L A N D Irish Council
Page 3 and 4:
FUNCTIONS OF THE IRISH COUNCIL FOR
Page 5 and 6:
2 CONTENTS 6.5 Healthcare - Medical
Page 7 and 8:
4 1.0 EXECUTIVE SUMMARY Knowledge e
Page 9 and 10:
6 Nanotechnology - National Roadmap
Page 11 and 12:
8 Assuming that the recommendations
Page 13 and 14:
10 A significant increase in the nu
Page 15 and 16:
12 2.0 INTRODUCTION 2.1 Background
Page 17 and 18:
14 2.5 Acknowledgements The Council
Page 19 and 20:
16 and lowered as it scans across t
Page 21 and 22:
18 Figure 3.3: Nanocrystals of the
Page 23 and 24:
20 4.0 ROADMAP 4.1 Background The n
Page 25 and 26:
22 4.4 Nanotechnology Enabled Produ
Page 27 and 28:
24 5.0 OPPORTUNITY 5.1 Background I
Page 29 and 30:
26 5.3 Improved Products and Proces
Page 31 and 32:
28 Figure 5.2: The launch of vehicl
Page 33 and 34:
30 An example of a multinational co
Page 35 and 36:
32 5.6 Conclusions Based on the abo
Page 37 and 38:
34 The above work for each sector w
Page 39 and 40:
36 Year of Production 2002 2004 200
Page 41 and 42:
38 Ireland should examine its curre
Page 43 and 44: 40 At the present time the photonic
Page 45 and 46: 42 6.4.2 Sector Roadmap From a tech
Page 47 and 48: 44 The growth of the medical device
Page 49 and 50: 46 Table 6.4: Challenges facing the
Page 51 and 52: 48 STAGE ONE: 1980 - 2000 STAGE TWO
Page 53 and 54: 50 it is possible that there will b
Page 55 and 56: 52 6.7.3 Intersection with Nanotech
Page 57 and 58: 54 6.8 Construction Sector 6.8.1 Se
Page 59 and 60: 56 More importantly, nanotechnology
Page 61 and 62: 58 7.0 CAPABILITY 7.1 Background Th
Page 63 and 64: 60 Higher Education Authority; thro
Page 65 and 66: 62 Enterprise Ireland is seeking to
Page 67 and 68: 64 Elan Corporation develops and ma
Page 69 and 70: 66 There are at least six establish
Page 71 and 72: 68 In respect of the second issue,
Page 73 and 74: 70 9.0 NATIONAL NANOTECHNOLOGY FORU
Page 75 and 76: 72 9.3 Conclusions The immediate es
Page 77 and 78: 74 The co-ordination of the funding
Page 79 and 80: 76 10.4 Conclusions The above strat
Page 81 and 82: 78 APPENDIX II Appendix II: Task Fo
Page 83 and 84: 80 Wednesday, 5th March 2003, Gover
Page 85 and 86: 82 Europe - Commission Nanotechnolo
Page 87 and 88: 84 Another important aspect of fund
Page 89 and 90: 86 Enterprise Ireland has already d
Page 91 and 92: 88 2. What is Nanotechnology? Nanot
Page 93: 90 For example the application of n
Page 97 and 98: 94 3.2. Market development timescal
Page 99 and 100: 96 There are two start-up nanotechn
Page 101 and 102: 98 4.3 Established EI Clients A num
Page 103 and 104: 100 6. Primary targets for the deve
Page 105 and 106: 102 Objective 3. Increase the numbe
Page 107 and 108: 104 Objective 7. Assist researchers
Page 109 and 110: 106 Potential industrial adopters n
Page 111 and 112: 108 Section 2 - National and Intern
Page 113 and 114: 110 ii. Technology Development Rese
Page 115 and 116: 112 UCD Prof. Donald 961,000 Using
Page 117 and 118: 114 5. European Union Funding via F
Page 119 and 120: 116 UCD HPMD-CT-2000-00014 0.45 Cha
Page 121 and 122: 118 Communications Communications i
Page 123 and 124: 120 (b) SMEs that are inventors of
Page 125 and 126: 122 Dr. Pat Morgan Dean, Faculty of
Page 127 and 128: 124 A Partnership Approach to Resea
Page 129: July 2004
show all

ICSTI Statement on Nanotechnology - Forfás

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?